Trial Profile

An Open Label, Phase Ib/II Trial of LVGN6051 Combined with Anlotinib in the Treatment of Locally Advanced, Metastatic or Recurrent Refractory Soft Tissue Sarcoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary) ; Exlinkibart (Primary)
Indications Soft tissue sarcoma
Focus Adverse reactions; Therapeutic Use
Sponsors Lyvgen Biopharma

Most Recent Events

04 Jun 2024 Results (n=39; As of Jan 22, 2024) assessing the safety and efficacy of LVGN6051 combined with anlotinib for refractory soft tissue sarcoma, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
31 May 2022 Status changed from not yet recruiting to recruiting.
05 Apr 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com